Profile data is unavailable for this security.
About the company
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
- Revenue in USD (TTM)54.98bn
- Net income in USD7.77bn
- Incorporated1992
- Employees94.30k
- LocationAstraZeneca PLC1 Francis Crick AvenueCambridge Biomedical CampusCAMBRIDGE CB2 0AAUnited KingdomGBR
- Phone+44 207 304 5000
- Fax+44 207 604 8151
- Websitehttps://www.astrazeneca.com/
Mergers & acquisitions
| Acquired company | AZN:LSE since announced | Transaction value |
|---|---|---|
| Esobiotec Srl | -12.49% | 1.00bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc | 11.10bn | -988.90m | 121.30bn | 6.10k | -- | 7.36 | -- | 10.93 | -3.88 | -3.88 | 42.86 | 64.20 | 0.4744 | 1.43 | 6.17 | 1,819,623.00 | -4.23 | 14.06 | -5.04 | 16.67 | 86.03 | 87.35 | -8.91 | 26.28 | 2.29 | -- | 0.0067 | 0.00 | 11.66 | 21.50 | -114.80 | -- | 45.11 | -- |
| Gilead Sciences Inc | 28.74bn | 5.97bn | 139.43bn | 17.60k | 23.71 | 7.28 | 15.96 | 4.85 | 4.73 | 4.73 | 22.79 | 15.39 | 0.5098 | 3.45 | 6.35 | 1,632,671.00 | 10.58 | 5.26 | 13.63 | 6.38 | 78.29 | 78.47 | 20.76 | 12.54 | 1.23 | 7.80 | 0.5667 | 108.47 | 6.04 | 5.08 | -91.53 | -38.34 | -8.71 | 4.10 |
| Pfizer Inc | 62.46bn | 7.87bn | 144.12bn | 81.00k | 18.39 | 1.60 | 9.74 | 2.31 | 1.38 | 1.38 | 10.95 | 15.89 | 0.2911 | 1.46 | 5.47 | 771,148.10 | 3.68 | 7.45 | 4.49 | 9.43 | 74.57 | 69.10 | 12.64 | 20.37 | 0.9604 | 12.26 | 0.4066 | 64.22 | 6.84 | 9.10 | 275.82 | -5.27 | 2.32 | 3.13 |
| Amgen Inc | 34.13bn | 5.93bn | 159.71bn | 28.00k | 27.11 | 25.73 | 13.85 | 4.68 | 10.96 | 10.96 | 63.05 | 11.54 | 0.3743 | 1.59 | 4.58 | 1,218,786.00 | 6.51 | 8.43 | 8.50 | 10.66 | 64.07 | 72.81 | 17.39 | 21.90 | 0.878 | 7.06 | 0.9024 | 71.37 | 18.57 | 7.43 | -39.11 | -12.21 | 12.14 | 9.18 |
| Merck & Co Inc | 63.92bn | 17.43bn | 210.10bn | 75.00k | 12.18 | 4.36 | 9.50 | 3.29 | 6.87 | 6.87 | 25.19 | 19.21 | 0.5786 | 2.31 | 5.77 | 852,293.30 | 15.79 | 9.52 | 20.46 | 12.64 | 77.07 | 73.47 | 27.30 | 17.87 | 1.16 | 23.90 | 0.4186 | 72.96 | 6.74 | 10.40 | 4,589.59 | 24.64 | -0.5885 | 6.66 |
| AstraZeneca PLC (ADR) | 54.98bn | 7.77bn | 221.99bn | 94.30k | 28.83 | 5.42 | 17.24 | 4.04 | 2.49 | 2.49 | 17.60 | 13.23 | 0.5273 | 1.73 | 4.52 | 583,054.10 | 7.46 | 4.32 | 10.35 | 5.95 | 82.36 | 80.22 | 14.15 | 9.39 | 0.6954 | 10.42 | 0.4348 | 107.68 | 18.03 | 17.27 | 18.14 | 39.43 | 13.27 | -- |
| Holder | Shares | % Held |
|---|---|---|
| PRIMECAP Management Co.as of 31 Mar 2025 | 40.66m | 1.31% |
| Wellington Management Co. LLPas of 31 Mar 2025 | 34.58m | 1.12% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2025 | 31.29m | 1.01% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Mar 2025 | 29.81m | 0.96% |
| T. Rowe Price International Ltd.as of 31 Mar 2025 | 27.28m | 0.88% |
| Managed Account Advisors LLCas of 31 Mar 2025 | 22.52m | 0.73% |
| Fisher Asset Management LLCas of 31 Mar 2025 | 20.17m | 0.65% |
| Sanders Capital LLCas of 31 Mar 2025 | 15.07m | 0.49% |
| Jennison Associates LLCas of 31 Mar 2025 | 10.56m | 0.34% |
| Strategic Advisers LLCas of 31 Mar 2025 | 9.51m | 0.31% |
